SML0877
Gardiquimod
≥98% (HPLC)
Synonym(s):
1-(4-Amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol, 4-Amino-2-[(ethylamino)methyl]-?,?-dimethyl-1H-Imidazo[4,5-c]quinoline-1-ethanol
Sign In to View Organizational & Contract Pricing.
Select a Size
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C17H23N5O
CAS Number:
Molecular Weight:
313.40
NACRES:
NA.77
UNSPSC Code:
51111800
Product Name
Gardiquimod, ≥98% (HPLC)
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Related Categories
Biochem/physiol Actions
Gardiquimod is a potent and specific agonist for human or mouse Toll-like receptor 7 (TLR7).
Gardiquimod is a potent and specific agonist for human or mouse Toll-like receptor 7 (TLR7). Also, at high concentration gardiquimod activates TLR8. Similarly to imiquimod, gardiquimod could mimic the effects of viral nucleic acids on the immune system.
Gardiquimod is developed as a new imidazoquinoline compound. It stimulates NF-κB (nuclear factor-κB) activation in cells expressing human or murine toll like receptor 7 (TLR7). Gardiquimod is found to be ten times more efficient than imiquimod. It induces splenocyte activation and prevents murine B16 melanoma growth and metastasis. Gardiquimod might serve as a therapeutic agent to prevent HIV-1 (human immunodeficiency virus - 1) transmission. It hinders the life cycle of HIV-1, by blocking the action of HIV-1 reverse transcriptase.
Features and Benefits
This compound is featured on the Cytokine Receptors (Interleukin-1 Receptor/TIR Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
Ma F, et al.
Cellular & Molecular Immunology, 7(5), 381-381 (2010)
Maarten Buitendijk et al.
AIDS research and human retroviruses, 29(6), 907-918 (2013-01-16)
Immune response modifiers are being studied as therapeutic agents for viral infections and cancer. These molecules include agonists for the Toll-like receptors (TLR), a family of innate immune receptors. TLR7 and 8, located in cellular endosomes, bind single-stranded RNA characteristic
Rosmely Hernandez et al.
Journal for immunotherapy of cancer, 9(9) (2021-09-04)
Immunization with tumor neoantigens is a promising vaccine approach to promote antitumor immunity due to their high immunogenicity, lack of expression in normal tissue, and preferential induction of tumor neoantigen-specific T cells, which are central mediators of the anti-cancer response.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service